ERBB2 and breast cancer: The results of a study on adverse reactions of targeted drugs for HER2-positive breast cancer (Fang et al., 2022) showed that all patients had varying degrees of diarrhea from 1 to 7 days after the first dose (2.76 ± 2.17 days).